Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 4/2024

Inhalt (15 Artikel)

Open Access Research

Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma

Zhengjie Dai, Xuan Lin, Xu Wang, Xuan Zou, Yu Yan, Ruijie Wang, Yusheng Chen, Yesiboli Tasiheng, Mingjian Ma, Xu Wang, He Cheng, Xianjun Yu, Chen Liu

Open Access Research

Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinoma

Xinru Fan, Zijun Yan, Yunkai Lin, Qing Wang, Li Jiang, Xiaomeng Yao, Liwei Dong, Lei Chen, Tuan Zhao, Jieqiong Zhao, Heping Hu, Hui Wang

Open Access Research

Riboflavin-LSD1 axis participates in the in vivo tumor-associated macrophage morphology in human colorectal liver metastases

Cristiana Soldani, Giulia De Simone, Michela Anna Polidoro, Aurelia Morabito, Barbara Franceschini, Federico Simone Colombo, Achille Anselmo, Flavio Milana, Ana Lleo, Guido Torzilli, Roberta Pastorelli, Matteo Donadon, Laura Brunelli

Open Access Review

Clinical immunotherapy in pancreatic cancer

Xiaorong Ye, Yue Yu, Xiaohu Zheng, Hongdi Ma

Open Access Research

Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity

Jiawei Yue, Hui Guo, Peng Xu, Jinhong Ma, Weifeng Shi, Yumin Wu

Open Access Research

Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer

Bingyu Li, Kaifeng Jin, Zhaopei Liu, Xiaohe Su, Ziyue Xu, Ge Liu, Jingtong Xu, Hailong Liu, Yuan Chang, Yiwei Wang, Yu Zhu, Zewei Wang, Le Xu, Weijuan Zhang

Open Access Research

Neutrophils seeking new neighbors: radiotherapy affects the cellular framework and the spatial organization in a murine breast cancer model

C. M. Reichardt, M. Muñoz-Becerra, A. Rius Rigau, M. Rückert, R. Fietkau, G. Schett, U. S. Gaipl, B. Frey, L. E. Muñoz

Open Access Research

Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy

Lujun Shen, Hongtong Tan, Juan Nie, Yiquan Jiang, Gulijiayina Nuerhashi, Han Qi, Fei Cao, Chunyong Wen, Shuanggang Chen, Tianqi Zhang, Wei Zheng, Peng Liu, Ying Liu, Tao Huang, Dandan Li, Xiaoshi Zhang, Weijun Fan

Open Access Research

Construction of an immune predictive model and identification of TRIP6 as a prognostic marker and therapeutic target of CRC by integration of single-cell and bulk RNA-seq data

Wenjun Liu, Xitu Luo, Zilang Zhang, Yepeng Chen, Yongliang Dai, Jianzhong Deng, Chengyu Yang, Hao Liu

Open Access Research

Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma

Tanguy Y. Seiwert, Sophie Wildsmith, Jérôme Fayette, Kevin Harrington, Maura Gillison, Myung-Ju Ahn, Shunji Takahashi, Jared Weiss, Jean-Pascal Machiels, Shrujal Baxi, Valerie Baker, Brent Evans, Nassim Morsli, Jill Walker, Katia Real, Anne L’Hernault, Amanda Psyrri

Open Access Research

Molecular classification reveals the sensitivity of lung adenocarcinoma to radiotherapy and immunotherapy: multi-omics clustering based on similarity network fusion

Jianguo Zhang, Yangyi Li, Weijing Dai, Fang Tang, Lanqing Wang, Zhiying Wang, Siqi Li, Qian Ji, Junhong Zhang, Zhengkai Liao, Jing Yu, Yu Xu, Jun Gong, Jing Hu, Jie Li, Xiuli Guo, Fajian He, Linzhi Han, Yan Gong, Wen Ouyang, Zhihao Wang, Conghua Xie

Open Access Research

A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer

Gerald S. Falchook, James Reeves, Sunil Gandhi, David R. Spigel, Edward Arrowsmith, Daniel J. George, Janet Karlix, Gayle Pouliot, Maureen M. Hattersley, Eric T. Gangl, Gareth D. James, Jeff Thompson, Deanna L. Russell, Bhavickumar Patel, Rakesh Kumar, Emerson Lim

Open Access Research

Oct4 activates IL-17A to orchestrate M2 macrophage polarization and cervical cancer metastasis

Zhuoqiong Bian, Xiaoling Wu, Qing Chen, Qing Gao, Xiang Xue, Yidong Wang

Open Access Research

Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China

Huan Yan, Lianxi Song, Yizhi Li, Qinqin Xu, Wenhuan Guo, Shaoding Lin, Wenjuan Jiang, Zhan Wang, Li Deng, Zhe Huang, Haoyue Qin, Xing Zhang, Fan Tong, Ruiguang Zhang, Zhaoyi Liu, Lin Zhang, Juan Yu, Xiaorong Dong, Qian Gong, Jun Deng, Xue Chen, Jing Wang, Gao Zhang, Nong Yang, Yongchang Zhang, Liang Zeng

Open Access Research

Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer

Kaiqi Zhang, Yuan Xu, Xusheng Chang, Caili Xu, Wenjing Xue, Dan Ding, Mingming Nie, Hui Cai, Jun Xu, Lu Zhan, Jiangbo Han, Tiancai Cai, Dianwen Ju, Li Feng, Xuyao Zhang, Kai Yin

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.